dexamfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	841	51-64-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dextroamphetamine S-Amphetamine D-Amphetamine dexadrine dexamfetamine dextroamphetamine sulfate dextroamphetamine saccharate dextroamphetamine adipate dextroamphetamine resin complex	The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. Molecular weight: 135.21 Formula: C9H13N CLOGP: 1.74 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 26.02 ALOGS: -1.89 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dextroamphetamine
S-Amphetamine
D-Amphetamine
dexadrine
dexamfetamine
dextroamphetamine sulfate
dextroamphetamine saccharate
dextroamphetamine adipate
dextroamphetamine resin complex

The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

Molecular weight: 135.21
Formula: C9H13N
CLOGP: 1.74
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 26.02
ALOGS: -1.89
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.40 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Sept. 9, 1955	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coronary artery dissection	70.62	15.58	17	6865	710	50597532
Anxiety	69.53	15.58	102	6780	177504	50420738
Migraine	65.60	15.58	65	6817	75215	50523027
Pre-existing condition improved	54.13	15.58	24	6858	7073	50591169
Depression	48.12	15.58	83	6799	165340	50432902
Cataplexy	45.61	15.58	13	6869	1053	50597189
Suspected product quality issue	37.31	15.58	8	6874	197	50598045
Feeling abnormal	36.50	15.58	63	6819	125429	50472813
Product substitution issue	36.16	15.58	23	6859	14034	50584208
Sleep apnoea syndrome	27.29	15.58	24	6858	23844	50574398
Therapeutic response unexpected	26.66	15.58	20	6862	15895	50582347
Neuroleptic malignant syndrome	25.65	15.58	17	6865	11113	50587129
Suicidal ideation	24.83	15.58	34	6848	55351	50542891
Somnolence	23.96	15.58	60	6822	154925	50443317
Weight decreased	23.74	15.58	75	6807	221170	50377072
Overdose	22.61	15.58	45	6837	99682	50498560
Memory impairment	20.68	15.58	38	6844	79322	50518920
Rhabdomyolysis	19.08	15.58	25	6857	39002	50559240
Disturbance in attention	18.48	15.58	22	6860	31164	50567078
Snoring	18.23	15.58	9	6873	3375	50594867
Hypothermia	17.72	15.58	14	6868	12002	50586240
Headache	16.83	15.58	122	6760	506413	50091829
Muscle rigidity	15.68	15.58	12	6870	9817	50588425
Serotonin syndrome	15.58	15.58	18	6864	24695	50573547

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oppositional defiant disorder	111.83	25.12	23	3643	508	29570353
Decreased eye contact	107.98	25.12	22	3644	463	29570398
Bruxism	91.57	25.12	24	3642	1563	29569298
Aggression	91.15	25.12	56	3610	35485	29535376
Coordination abnormal	80.36	25.12	31	3635	7083	29563778
Crying	77.56	25.12	28	3638	5323	29565538
Homicidal ideation	76.23	25.12	23	3643	2501	29568360
Product substitution issue	72.73	25.12	31	3635	9141	29561720
Suicidal ideation	72.33	25.12	48	3618	34668	29536193
Anxiety	62.16	25.12	64	3602	85301	29485560
Choreoathetosis	61.61	25.12	16	3650	1004	29569857
Poor quality sleep	59.18	25.12	25	3641	7208	29563653
Affect lability	57.66	25.12	20	3646	3382	29567479
Trismus	56.39	25.12	18	3648	2355	29568506
Mood altered	50.06	25.12	23	3643	8088	29562773
Insomnia	48.05	25.12	57	3609	88704	29482157
Irritability	47.00	25.12	31	3635	22121	29548740
Psychomotor hyperactivity	46.69	25.12	22	3644	8191	29562670
Speech disorder	45.31	25.12	31	3635	23485	29547376
Depression	43.33	25.12	53	3613	85094	29485767
Streptococcal infection	41.73	25.12	17	3649	4471	29566390
Hyperkinesia	41.61	25.12	13	3653	1586	29569275
Posterior reversible encephalopathy syndrome	38.94	25.12	20	3646	8956	29561905
Dyskinesia	37.59	25.12	26	3640	20035	29550826
Sleep disorder	37.44	25.12	28	3638	24358	29546503
Depressed mood	32.42	25.12	22	3644	16426	29554435
Dystonia	31.87	25.12	18	3648	9731	29561130
Extrasystoles	31.75	25.12	13	3653	3461	29567400
Hypertensive emergency	31.29	25.12	9	3657	827	29570034
Therapeutic response unexpected	31.11	25.12	17	3649	8621	29562240
Supraventricular extrasystoles	30.31	25.12	12	3654	2929	29567932
Sleep apnoea syndrome	28.78	25.12	21	3645	17578	29553283
Drug ineffective	28.58	25.12	104	3562	363066	29207795
Tic	28.07	25.12	10	3656	1825	29569036
Product complaint	26.24	25.12	13	3653	5392	29565469
Educational problem	25.79	25.12	7	3659	520	29570341

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oppositional defiant disorder	114.24	16.95	23	7830	463	64490416
Decreased eye contact	98.35	16.95	22	7831	743	64490136
Anxiety	85.66	16.95	114	7739	202535	64288344
Aggression	80.76	16.95	57	7796	46175	64444704
Bruxism	80.47	16.95	26	7827	3598	64487281
Product substitution issue	75.84	16.95	39	7814	17822	64473057
Homicidal ideation	74.90	16.95	24	7829	3233	64487646
Coronary artery dissection	73.76	16.95	18	7835	892	64489987
Suicidal ideation	58.58	16.95	55	7798	66487	64424392
Coordination abnormal	55.91	16.95	30	7823	14934	64475945
Crying	55.37	16.95	33	7820	20057	64470822
Depression	53.96	16.95	87	7766	183204	64307675
Choreoathetosis	51.86	16.95	15	7838	1432	64489447
Affect lability	45.14	16.95	22	7831	8968	64481911
Poor quality sleep	44.24	16.95	28	7825	18923	64471956
Trismus	43.94	16.95	18	7835	4883	64485996
Mood altered	40.81	16.95	25	7828	15954	64474925
Overdose	40.61	16.95	71	7782	159495	64331384
Psychomotor hyperactivity	40.50	16.95	24	7829	14427	64476452
Dyskinesia	37.44	16.95	34	7819	39354	64451525
Hyperkinesia	35.89	16.95	13	7840	2533	64488346
Irritability	35.48	16.95	32	7821	36714	64454165
Speech disorder	35.08	16.95	36	7817	48405	64442474
Sleep disorder	33.85	16.95	39	7814	59670	64431209
Streptococcal infection	33.68	16.95	17	7836	7462	64483417
Feeling abnormal	32.12	16.95	58	7795	133544	64357335
Insomnia	31.07	16.95	72	7781	197764	64293115
Dystonia	30.03	16.95	22	7831	18843	64472036
Intentional overdose	29.62	16.95	45	7808	89899	64400980
Tic	28.28	16.95	11	7842	2608	64488271
Educational problem	27.76	16.95	7	7846	397	64490482
Cataplexy	27.07	16.95	8	7845	823	64490056
Extrasystoles	26.71	16.95	14	7839	6644	64484235
Supraventricular extrasystoles	25.34	16.95	13	7840	5902	64484977
Posterior reversible encephalopathy syndrome	24.18	16.95	21	7832	22925	64467954
Intentional self-injury	23.63	16.95	23	7830	29021	64461858
Nervousness	23.29	16.95	23	7830	29533	64461346
Therapeutic response unexpected	23.02	16.95	18	7835	16983	64473896
Hypertensive emergency	22.61	16.95	9	7844	2267	64488612
Abnormal behaviour	22.57	16.95	24	7829	33598	64457281
Cardio-respiratory arrest	21.48	16.95	41	7812	98352	64392527
Suicide attempt	21.24	16.95	34	7819	70973	64419906
Agitation	20.76	16.95	38	7815	88329	64402550
Neutrophil hypersegmented morphology present	20.75	16.95	3	7850	6	64490873
Depressed mood	20.29	16.95	25	7828	40987	64449892
Neutropenia	19.40	16.95	3	7850	239621	64251258
Pre-existing condition improved	19.06	16.95	10	7843	4752	64486127
Fatigue	18.16	16.95	154	7699	748576	63742303
Anaemia	18.03	16.95	12	7841	378668	64112211
Somnolence	17.90	16.95	60	7793	203585	64287294
Anger	17.79	16.95	15	7838	15726	64475153
Product quality issue	17.79	16.95	20	7833	29779	64461100
Migraine	17.38	16.95	29	7824	62648	64428231

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BA02	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:48560	dopaminergic agents
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitor
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
FDA PE	N0000175729	Central Nervous System Stimulation
FDA EPC	N0000175739	Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Narcolepsy	indication	60380001	DOID:8986
Attention deficit hyperactivity disorder	indication	406506008
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Dependent drug abuse	contraindication	6525002
Bipolar disorder	contraindication	13746004	DOID:3312
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Anorexia nervosa	contraindication	56882008	DOID:8689
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Cardiomyopathy	contraindication	85898001	DOID:0050700
Weight loss	contraindication	89362005
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.89	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
13.5MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	9456993	Oct. 24, 2033	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
18MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	9456993	Oct. 24, 2033	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
4.5MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	9456993	Oct. 24, 2033	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
9MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	9456993	Oct. 24, 2033	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
13.5MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	March 22, 2025	NEW PRODUCT
18MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	March 22, 2025	NEW PRODUCT
4.5MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	March 22, 2025	NEW PRODUCT
9MG/9HR	XELSTRYM	NOVEN PHARMS INC	N215401	March 22, 2022	RX	SYSTEM	TRANSDERMAL	March 22, 2025	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Synaptic vesicular amine transporter	Transporter	Q05940	VMAT2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	7	IUPHAR	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	RELEASING AGENT	Ki	6.68	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN				WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein	Transcription factor	Q16568	CART_HUMAN				WOMBAT-PK
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		Ki	4.84	CHEMBL
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		EC50	6.87	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN				WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.24	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.18	PDSP
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		EC50	5.75	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	5.31	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		Ki	4.91	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_MACMU		EC50	6	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_RAT		EC50	7.25	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_MOUSE		EC50	8.70	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		Kd	5.35	CHEMBL

External reference:

ID	Source
4019978	VUID
N0000148062	NUI
D02078	KEGG_DRUG
51-63-8	SECONDARY_CAS_RN
350708-40-6	SECONDARY_CAS_RN
64770-52-1	SECONDARY_CAS_RN
221088	RXNORM
4018004	VANDF
4018005	VANDF
4018835	VANDF
4019978	VANDF
C0011812	UMLSCUI
CHEBI:4469	CHEBI
1WE	PDB_CHEM_ID
CHEMBL612	ChEMBL_ID
CHEMBL3544971	ChEMBL_ID
CHEMBL3989844	ChEMBL_ID
DB01576	DRUGBANK_ID
2147	IUPHAR_LIGAND_ID
TZ47U051FI	UNII
5826	PUBCHEM_CID
1604	MMSL
40549	MMSL
4563	MMSL
4564	MMSL
d00804	MMSL
001793	NDDF
001795	NDDF
006720	NDDF
387022005	SNOMEDCT_US
387278002	SNOMEDCT_US
45207006	SNOMEDCT_US
50868004	SNOMEDCT_US
D003913	MESH_DESCRIPTOR_UI
CHEMBL1200782	ChEMBL_ID
1430	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine SulfateExtended-ReleaseExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1702	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Dextroamphetamine SulfateExtended-ReleaseExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1703	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Dextroamphetamine SulfateExtended-ReleaseExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1704	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA AUTHORIZED GENERIC	23 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9927	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	16 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9928	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	NDA AUTHORIZED GENERIC	16 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9929	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA AUTHORIZED GENERIC	16 sections